This week, five pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
NuPathe Inc.’s (PATH) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.
Tetraphase Pharmaceuticals, Inc. (TTPH) gets a higher grade this week, advancing from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of TTPH stock.
Watson Pharmaceuticals (WPI) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
This week, Impax Laboratories, Inc. (IPXL) pushes up from a C to a B rating. Impax Laboratories develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. For more information, get Portfolio Grader’s complete analysis of IPXL stock.
Mylan’s (MYL) ratings are looking better this week, moving up to an A from last week’s B. Mylan is a global generic and specialty pharmaceuticals company. For more information, get Portfolio Grader’s complete analysis of MYL stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.